

Benefits analysis – a quick summary of recent developments and activities

Mike Holland, mike.holland@emrc.co.uk

Task Force on Integrated Assessment Modelling

Paris, May 2017



Recent developments

- **Methods**
 - COMEAP, DG ENV and NO₂
 - COMEAP cardiovascular morbidity
 - Interpretation of air quality and health impacts
 - Guidelines for BCA (Gates Foundation)
 - REACH and socio-economic analysis, OECD SACAME Project
- **Policy analysis**
 - BAT assessment and IED derogation
 - Continued involvement of international organisations (e.g. CCAC, OECD)
 - Wider international interest at government and company levels
 - OECD, Australia, South Africa
 - Local interest
 - NHS in UK

COMEAP, DG ENV, NO₂

- Growing literature (post HRAPIE)
- Issues under review:
 - ‘Thresholds’, ‘cut-points’ ?
 - Size of response function ?
 - Overlap with PM ?
 - Correct modelling of concentration in relation to the epidemiological studies
- COMEAP – UK Committee on the Medical Effects of Air Pollutants

NO₂: HRAPIE, COMEAP positions

		Band	RR	Averaging	Overlap with PM
Mortality, all ages	Acute	A*	1.0027	Daily 1 hr max, all	-
Resp. Hosp Admissions, all ages	Acute	A*	1.018	24 hr mean, all	-
Bronchitis ages 5-14	Chronic	B*	1.021	Annual, all	-
Mortality, ages 30+	Chronic	B*	1.055	Annual >20ug.m ⁻³	Up to 33%
COMEAP position					
Mortality, ages 30+	Chronic	B*	1.025	Annual (no threshold)	?

New report headlines: Range of impacts linked to air pollution

- Link to many diseases including:
 - Cancer
 - Diabetes
 - Asthma
 - Obesity
 - Stroke
 - Dementia
 - Heart disease



Ongoing COMEAP work on cardiovascular morbidity

- Focus on effects of chronic exposure
- Mechanisms group has provided draft report
- Epidemiology / impact assessment group will produce draft later this year (?)
 - Use of microsimulation approaches for health impact assessment
 - Consideration of whether microsimulation offers significant benefits for air quality policy work

Health impact functions – review work elsewhere

- WHO process
- Other countries ?
 - Useful to know what else is going on

Interpretation of impacts



David Spiegelhalter

Follow

Statistician, communicator about evidence, risk, probability, chance, uncertainty, etc. Chair, Winton C...

Feb 20 · 11 min read

Does air pollution kill 40,000 people each year in the UK?

Air pollution is news. The Daily Mail claims that *Air pollution is 'killing 40,000 a year in the UK'* Greenpeace says *40,000 lives were cut short by air pollution in the U.K.*, while the Guardian reports *Air pollution crisis 'plagues' UK, finds UN human rights expert.* But where does the 40,000 figure come from, what does it mean, and is there really a 'crisis'? I discovered that digging down to the basis for this figure required some statistical detective work, so brace yourself for some forensic details...



Calculation of the 40,000 figure

- COMEAP: PM_{2.5} deaths = 29,000
 - <https://www.gov.uk/government/publications/comeap-mortality-effects-of-long-term-exposure-to-particulate-air-pollution-in-the-uk>
- Defra: NO₂ deaths = 23,500
 - https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/460401/air-quality-econanalysis-nitrogen-interim-guidance.pdf
- Combined = 40,000 +/-25%
 - Assumes greater overlap than Defra

COMEAP results in more detail

Table 1. COMEAP results for effects of outdoor PM_{2.5} exposure on mortality for the UK²

Measure of mortality	Impact
Number of attributable deaths	28,861
Attributable deaths per 100,000 aged over 30 years	75
Burden on total survival (life-years lost)	340,000
Difference in life expectancy for the 2008 cohort (days)	
Females	194
Males	182

Highlights different ways of representing mortality impacts of air pollution

Averages at ~12 years of lost life expectancy per equivalent attributable death



Consequences for valuation

- Real number of deaths ‘linked’ to air pollution is likely higher than estimates derived from analysis (COMEAP)
- But effect for average affected individual can be small
- Interpret 40,000 (or other) estimate as ‘equivalent attributable deaths’
 - Provides support for using the VSL
- But estimate of life years lost requires less ‘interpretation’
 - Provides support for continuing to use the VOLY
- Highlights need for care in understanding impacts in order to get the unit values right

Guidelines for Benefit Cost Analysis (Gates Foundation)

- Workshop May 11th Seattle (deadline for registration 4th May: <https://sites.sph.harvard.edu/bcaguidelines/scoping/>)



HARVARD
T.H. CHAN | **SCHOOL OF PUBLIC HEALTH**
Powerful Ideas for a healthier world

Guidelines for Benefit-Cost Analysis

HOME WHAT WE ARE DOING ▾ WHO WE ARE HOW TO PARTICIPATE ▾



Scoping Workshop

May 11, 2017

Guidelines for Benefit Cost Analysis (Gates Foundation)

- Scoping phase:
 - Identify currently available guidance
 - Examine commonalities, differences, gaps
 - Identify major funders and users of benefit-cost analysis
 - Explore major challenges
 - Review recent benefit-cost analyses
 - Develop plans for Phase 2

Other initiatives: REACH and socio-economic analysis (SEA)

- Regulation on Registration, Evaluation, Authorisation and Restriction of Chemicals
- Introduced by EU in 2006
- Requires SEA for restriction proposals and some authorisation applications
- Some common ground with air quality:
 - Mercury, lead, some VOCs
 - Some major air pollutant emitters

Other initiatives: Valuation studies under REACH SEA

- Skin and respiratory sensitisation
- Kidney failure
- Infertility and developmental problems
- Cancer
- https://echa.europa.eu/documents/10162/13630/echa_review_wtp_en.pdf



Valuing selected health impacts
of chemicals

Summary of the Results and a Critical Review of
the ECHA study


ECHA Cancer valuations

Table A 2: Estimates of values of statistical life, case of cancer and morbidity due to cancer based on the estimates in Table A1

	Willingness-to-pay (WTP) (€₂₀₁₂) for EU28 (rounded)	Scaled¹⁾ WTP values (€₂₀₁₂) for EU28 [unscaled, raw values in brackets]
Value of statistical life (VSL)	3,500,000	3,517,094 [3,003,496]
Value of a statistical case of cancer (VSCC)	350,000	354,651 [302,862]
Value of cancer morbidity (VCM)	410,000	410,653 [350,686]

Other initiatives: SACAME

- “Socio-economic Analysis of Chemicals by Allowing a better quantification and monetisation of Morbidity and Environmental impacts”
- <http://www.oecd.org/fr/env/outils-evaluation/sacame.htm>



The screenshot shows the OECD website interface. At the top left is the OECD logo with the tagline "DES POLITIQUES MEILLEURES POUR UNE VIE MEILLEURE". A navigation bar contains "Accueil de l'OCDE", "A propos", "Pays", and "Thèmes". A breadcrumb trail reads: "Accueil de l'OCDE > Direction de l'Environnement > Outils et évaluation des politiques de l'environnement > The costs and benefits of regulating chemicals". A sidebar on the left lists various environmental topics, with "Sécurité des produits chimiques et biosécurité" selected. The main content area features the title "The costs and benefits of regulating chemicals" and a section titled "THE SACAME PROJECT".

THE SACAME PROJECT

SACAME stands for the **S**ocio-economic **A**nalysis of **C**hemicals by **A**llowing a better quantification and monetisation

Under the REACH legislation as well as other national legislations for managing chemicals, socio-economic analysis is an important part of the decision-making process and consists of an action for society as a whole when taking decisions on restrictions and authorisations processes. Market analysis contains a description of the risks as well as information on the health and environmental benefits, the associated costs and benefits. This analysis is also important for policy makers in justifying the value of investment of public funds in a chemicals management strategy.

This research builds on the OECD's work on quantifying the social costs of environmental externalities, particularly in

IED derogation assessment tool

- Provided by the Environment Agency in England and equivalents in devolved administrations
- <https://www.gov.uk/government/publications/industrial-emissions-directive-derogation-cost-benefit-analysis-tool/ied-derogation-cost-benefit-analysis-cba-tool-user-guide>

[Click here](#)
to start
your Cost-
Benefit
Analysis

The screenshot shows the top section of the tool's interface. On the left is the Environment Agency logo. To its right is a box containing the tool title 'IED Derogation Cost-Benefit Analysis Tool', the version number '6.15', and a redacted last update date. Further right is the Ricardo-AEA logo. Below these is a copyright notice for all users, stating the tool is the property of the Environment Agency and was developed by Ricardo-AEA in 2014. To the right of the notice are three red buttons: 'Tool Version History', 'Admin', and 'Your Input Version History'. At the bottom of the interface are four red buttons: 'Skip to results >>', 'Skip to summary >>', 'User guidance >>', and 'Underlying data >>'. A small number '18' is visible in the bottom right corner of the screenshot.

Environment Agency

IED Derogation Cost-Benefit Analysis Tool

Version Number: 6.15
Last Update: #*****#

RICARDO-AEA

Copyright and important notice for all users:

This model is the copyright of the Environment Agency. It was originally prepared by Ricardo-AEA under contract 'Development of IED derogation cost-benefit analysis tool and user guidance' (ED60335) dated 7 November 2014 and has been refined by the Environment Agency since. The contents of this model may not be reproduced in whole or in part, nor passed to any organisation or person without the specific prior written permission of the Environment Agency.

All users of this model are accordingly advised to undertake their own review of its assumptions, calculations and results before making any decision or entering into any commitment based on the information herein. No representation, warranty or undertaking (expressed or implied) is made by the Environment Agency or Ricardo-AEA for the adequacy, completeness or accuracy of the model or the assumptions on which it is based. The Environment Agency and Ricardo-AEA accept no liability whatsoever to any third party for any loss or damage arising from any interpretation or use of the information contained in this model, or reliance on any views expressed therein.

Tool Version History

Admin

Your Input Version History

Skip to results >>

Skip to summary >>

User guidance >>

Underlying data >>

18

Valuation data in the tool

Air Quality Damage Costs



[<Back to List](#)

Damage costs for use in analysis						
Uplift Rate	1.02	(?)				
Price base	0					
Original price base	2015					
IGCB NOX price base	2015					
Deflation factor	#N/A					
IGCB NOX Deflation factor	#N/A					

		Data Values - Input Here				
Pollutant	EEA Pollutant Name	IGCB damage costs			EEA values	
		Low central range	High central range	Central Estimate	£/tonne	
NOX Domestic	Nox	£ 5,859.00	£ 23,434.00	£ 14,646.00	£ 2,432.16	
NOX Agriculture	Nox	£ 2,020.00	£ 8,080.00	£ 5,050.00	£ 2,432.16	
NOX Waste	Nox	£ 4,343.00	£ 17,373.00	£ 10,858.00	£ 2,432.16	
NOX Industry	Nox	£ 5,253.00	£ 21,010.00	£ 13,131.00	£ 2,432.16	
NOX ESI	Nox	£ 505.00	£ 2,020.00	£ 1,263.00	£ 2,432.16	
SOX	SO2	£ 1,581.00	£ 2,224.00	£ 1,956.00	£ 9,860.55	
PM10 Domestic	PM10	£ 26,396.00	£ 38,311.00	£ 33,713.00	£ 17,041.49	
PM10 Agriculture	PM10	£ 9,103.00	£ 13,211.00	£ 11,625.00	£ 17,041.49	
PM10 Waste	PM10	£ 19,570.00	£ 28,403.00	£ 24,994.00	£ 17,041.49	
PM10 Industry	PM10	£ 23,665.00	£ 34,347.00	£ 30,225.00	£ 17,041.49	
PM10 ESI	PM10	£ 2,276.00	£ 3,303.00	£ 2,906.00	£ 17,041.49	
Ammonia	NH3	£ 1,843.00	£ 2,685.00	£ 2,363.00	£ 6,496.00	
Arsenic	Arsenic				£ 240,617.95	

Australian mining – damage guidance

- Previous analysis based on extrapolation of UK damage/tonne estimates to Australia



Pacific Environment Study

- Reviewed evidence, proposed alternative approach
- Limitations of economic approaches also identified
 - Need to ensure protection of small groups against high exposures



South African coal – power generation study

- Input to energy planning for South Africa
- Eskom seeking extensive derogations for coal plant



South African coal – power generation study

Population distribution



Impact assessment, estimated annual impacts from coal plant in South Africa

	Cases, etc	Value, \$int, millions
Equivalent attributable deaths		
<i>Lung cancer</i>	157	
<i>Ischaemic heart disease</i>	1,110	
<i>Chronic obstructive pulmonary disease</i>	73	
<i>Stroke</i>	719	
<i>Lower respiratory infection</i>	180	
Total equivalent attributable deaths	2,239	2,121.94
Chronic Bronchitis (adults, cases)	2,781	64.64
Bronchitis in children aged 6 to 12	9,533	2.19
Equivalent hospital admissions	2,379	2.79
Restricted Activity Days (all ages)	3,972,902	132.72
Asthma symptom days (children 5-19yr)	94,680	1.44
Lost working days	996,628	47.05
Total costs		2,372.78₄

NHS transport impacts study

- NHS is one of the world's largest employers

Employer	Employees		Headquarters
	2015 ^[1]	2010 ^{[2][3]}	
United States Department of Defense	3.2 million		United States
People's Liberation Army	2.3 million		China
Walmart	2.3 million		United States
McDonald's ^[note 1]	1.9 million	1.7 million	United States
National Health Service	1.7 million	1.4 million	United Kingdom
China National Petroleum Corporation	1.6 million	1.7 million	China
State Grid Corporation of China	1.5 million	1.6 million	China
Indian Railways	1.4 million		India
Indian Armed Forces	1.3 million		India
Hon Hai Precision Industry (Foxconn)	1.3 million	0.8 million	Taiwan ^[4]

NHS transport impacts study

- Impacts
 - Air pollution, accidents, noise, climate, benefits of active travel
- Scope
 - Staff commuting, business travel, patients, visitors, supply chain
- Resolution
 - Local level (hospital trusts, ambulance trusts, primary care providers)
- Results out soon!

Summary

- Benefits analysis and CBA continue to be used extensively across Europe and increasingly the world
- Growing convergence of approaches
- Broader range of health concerns are being addressed
 - But more need to be considered
- Limited further development regarding:
 - Ecosystem damage assessment
 - Integration of further health impacts
- Useful to know of further applications and developments at the national level (email mike.holland@emrc.co.uk)